Sagimet's Denifanstat/Resmetirom Combo Shows Rapid Cholesterol Reduction in Phase 1 Trial
Event summary
- Sagimet presented two posters at EASL 2026, including a Best of EASL selection on Phase 1 data for denifanstat/resmetirom combination in MASH.
- Phase 1 trial showed rapid reductions in total and LDL cholesterol levels after two weeks of treatment.
- Combination therapy was generally well-tolerated with no safety signals reported.
- Preclinical data revealed synergistic effects of the combination in MASH mouse models.
The big picture
Sagimet's Phase 1 data for the denifanstat/resmetirom combination adds to the growing body of evidence supporting dual-mechanism approaches in MASH treatment. The rapid cholesterol reduction observed in healthy adults suggests potential cardiovascular benefits, which could expand the therapeutic value proposition. The combination's synergistic effects in preclinical models highlight its potential to address both liver fat reduction and fibrosis, positioning it as a competitive option in the MASH space.
What we're watching
- Clinical Efficacy
- How the rapid cholesterol reduction will translate into long-term cardiovascular benefits for MASH patients.
- Regulatory Pathway
- Whether the Phase 1 data will accelerate the combination therapy's path to Phase 2 trials and potential approval.
- Competitive Positioning
- The pace at which Sagimet can differentiate its combination therapy in the crowded MASH treatment landscape.